TICOPA试验中多种复合结局工具测量的应答动态
TICOPA试验纳入206例早期未用过改善病情抗风湿药的银屑病关节炎患者,随机分为紧密控制组(每4周评估并升级治疗)和标准治疗组(每12周评估)。结果显示三种复合指标均能区分两组,但AUC分析仅PASDAS有显著差异,寡关节炎亚组差异减弱。
要点
- PASDAS、GRACE和CPDAI均能区分紧密控制与标准治疗组。
- AUC分析中仅PASDAS显示组间显著差异。
- 寡关节炎患者中复合指标区分能力减弱。
核心结论
- 复合疾病活动度指标能区分TICOPA治疗组,但寡关节炎患者差异减弱。
研究设计与样本
- TICOPA试验为随机对照试验,纳入206例早期未用过改善病情抗风湿药的银屑病关节炎患者,随机1:1分为紧密控制组(n=101)和标准治疗组(n=105)。
主要发现
- 所有复合指标在治疗组间均显示显著差异(p<0.0001)。
- AUC分析显示PASDAS在组间有显著差异,而GRACE和CPDAI无显著差异。
- 寡关节炎亚组中,各指标组间差异显著性大幅降低(PASDAS p=0.04;GRACE p=0.01;CPDAI p=0.04),AUC分析均无法区分组间差异。
临床怎么用
- 复合指标可用于银屑病关节炎试验中区分治疗强度,但寡关节炎患者需谨慎解读。
局限性
- 需进一步数据确定银屑病关节炎试验中首选的主要结局复合指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to evaluate the dynamics of treatment response with different composite measures in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. METHODS: Participants with early disease-modifying antirheumatic drug-naïve psoriatic arthritis (PsA) were randomised 1:1 to either tight control (TC; 4 weekly review with therapy escalation if criteria not met) or standard care (SC; 12 weekly review). We calculated modified versions of the Psoriatic ArthritiS Disease Activity Score (PASDAS), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Composite scorE (GRACE) and Composite Psoriatic Disease Activity Index (CPDAI) at baseline and 12 weekly to 48 weeks by blinded assessor. For missing data, we used the last observation carried forward. Comparison between groups was made by analysis of covariance and comparison of area under the curve (AUC). RESULTS: 206 people were randomised to TC (n=101) or SC (n=105). Significant differences between treatment groups were seen (p<0.0001 for all composite measures). AUC analysis demonstrated a significant difference between groups for the PASDAS but not GRACE and CPDAI. For participants with oligoarthritis, a significant difference between groups was seen for each measure, although the significance levels were greatly diminished (PASDAS, p=0.04; GRACE p=0.01; CPDAI p=0.04). For oligoarthritis using AUC analysis, none of the measures could distinguish between groups. CONCLUSIONS: Composite measures of disease activity were able to distinguish between TICOPA treatment arms, although differences were diminished for those with oligoarthritis. Further data are needed to inform the preferred composite measure for use as the primary outcome in PsA trials. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT01106079) and ISCRCTN registry (ISCRCTN30147736).
引用
- Coates LC, Mahmood F, Emery P, et al. The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. Ann Rheum Dis. 2017. PMID: 28606970. doi:10.1136/annrheumdis-2017-211137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。